CRISPR Therapeutics AG (CRSP)

Interesting day given the activity of Vertex today in the M&A space. Go CRSP!

Here’s how people got wiped on GME. Trying to stay short until bankruptcy, when bankruptcy wasn’t on the table. Now I see a bunch of biotech with high short interest at all time lows. Some biotech is now under $500 mil market cap but they don’t have debt, How much lower do you want? There’s a bunch $NVTA $BLI $CRSP, etc

Crispr is back to being a heavy weight in arkk.

Market will recognize this sector is less associated with inflation and war

The news wire shows another strategic hire of Dr. P.K Morrow for the final stretch to regulatory approval. Don't miss this important clue. Go CRSP, Goodluck to All CRSP faithful.

Data to be presented at EHA. The abstract, as of December 6, 15 of the 17 patients with T-cell lymphoma were able to be evaluated with CTX130. The overall response rate was 71% with 29% of patients experiencing a complete response. It had an acceptable safety profile.

Question: If gene editing is one-and-done, does the longer-term revenue stream from an effective therapy come only from new patients?

To invest in a company and make money is great. To invest in a company that cures diseases is heavenly.

CRSP stock price below $50 is a giveaway and a no brainer. Load up if you can and you'll be glad by end of the year.

Green

Cost basis is 125…wake me up in 5 years

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 2022 Bank of America Healthcare Conference on Wednesday, May 11, 2022, at 4:40 p.m. PT.

6 on going clinical trials going on, and the analyst move price targets down.

With 2.2 billion cash with 3.5 bill mc, time to accumulate

If you're not excited enough about CRSP, then see some their ongoing efforts to cure Type 1 diabetes

https://www.google.com/url?rct=j&sa=t&url=https://news.ubc.ca/2022/05/12/b-c-researchers-launching-clinical-trial-for-first-genetically-engineered-stem-cell-based-therapy-for-type-1-diabetes/&ct=ga&cd=CAEYBCoTODQxMzg4NDE0Mzk2OTc4MDUyNzIaYmE5OWYyY2RmZTZlNTk1ZTpjb206ZW46VVM&usg=AOvVaw0PU-xSItuabjA_-gCO5JGL